Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.63 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 5/20 | 0.57 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472119 | 0.93 | PGR (0.66) | FFAR1FFAR4HSD17B3HSD17B2MEN1 | |
| SCHEMBL26536740 | 0.83 | FFAR4 (0.60) | FFAR4HSD17B3HSD17B2MEN1KMT2A | |
| SCHEMBL1474307 | 0.81 | MAPT (0.73) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL12751017 | 0.81 | ALDH1A1 (0.51) | FFAR1FFAR4HSD17B3HSD17B2MEN1 | |
| SCHEMBL21497062 | 0.80 | PRMT1 (0.61) | FFAR1FFAR4HSD17B3HSD17B2MEN1 | |
| SCHEMBL29561893 | 0.80 | MEN1 (0.61) | HSD17B3HSD17B2MEN1KMT2AALDH1A1 | |
| SCHEMBL1471643 | 0.78 | BCL2L1 (0.52) | FFAR1FFAR4MEN1KMT2AALDH1A1 | |
| SCHEMBL7574073 | 0.78 | CA1 (0.62) | FFAR1FFAR4HSD17B3HSD17B2MEN1 | |
| SCHEMBL1471476 | 0.78 | LMNA (0.76) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL31596007 | 0.77 | FFAR1 (0.76) | FFAR1FFAR4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | FFAR1 4676/4885FFAR4 4806/4885HSD17B3 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.